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Background: Whether retinal microglia can maintain or restore immune homeostasis
during and after inflammation is unclear. We performed single-eye mRNA-sequencing on
microglia at different timepoints following a single inflammatory stimulus to characterise
their transcriptome during and after resolution of endotoxin-induced uveitis (EIU).
Experimental Approach: Cx3cr1CreER:R26-tdTomato (C57BL/6) male heterozygotes
were administered tamoxifen via different regimes at 4–5 weeks of age. Four weeks
post-tamoxifen, mice were injected intravitreally with 10 ng lipopolysaccharide (endotoxin
induced uveitis, EIU). Six-hundred retinal microglia were obtained by FACS from individual
naïve retinas and at 4 h, 18 h, and 2 weeks following EIU induction. Samples were
sequenced to a depth of up to 16.7million reads using the SMART-Seq v4 Ultra Low Input
RNA kit. The data was analysed using Partek software and Ingenuity Pathway Analysis.
Genes were considered differentially-expressed (DEG) if the FDR step-up p-value was
≤0.05 and the fold-change was ≥±2.
Results: Flow cytometric analysis indicates that the Cx3cr1CreER:R26-tdTomato strain
is both sensitive (>95% tagging) and specific (>95% specificity) for microglia when
tamoxifen is administered topically to the eye for 3 days. During “early” activation, 613
DEGs were identified. In contrast, 537 DEGs were observed during peak cellular infiltrate
and none at 2 weeks, compared to baseline controls (1,069 total unique DEGs). Key
marker changes were validated by qPCR, flow cytometry, and fluorescence microscopy.
C5AR1 was identified and validated as a robust marker of differentiating microglial
subsets during an LPS response.
Conclusion: Using EIU to provide a single defined inflammatory stimulus, mRNA-Seq
identified acute transcriptional changes in retinal microglia which returned to their original
transcriptome after 2 weeks. Yolk-sac derived microglia are capable of restoring their
homeostatic state after acute inflammation.
Keywords: microglia, transcriptome, uveitis, retina, resolution, mRNA-Seq, lipopolysaccharide (LPS),
heterogeneity
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INTRODUCTION
It has been challenging to investigate microglia during
inflammatory contexts primarily because distinguishing
them from infiltrating monocytes and macrophages has been
unreliable due to similar expression of cell-surface markers (1–6).
Microglia contribute to an immunosuppressive environment, are
derived from the yolk-sac, reside within two distinct niches in
the retina, and show differential regulation because of inherent
microglial heterogeneity (7, 8). Nonetheless conflicting data
remains on how microglia regulate or promote inflammation
depending on insult (9, 10). During inflammation microglia
alter their homeostatic state (8, 11–13). In acute inflammation,
markers including C5ar1 show promise in delineating sub-
populations of microglia mounting an LPS response (13). We
wished to determine if the microglial transcriptome resets after
an acute and resolving insult, or if homeostatic thresholds have
been reset or altered permanently.
Recent advancements in transgenic mouse lines, but also
in identification of markers that are “microglial-specific,” for
example Cd44, P2ry12, Siglech, and Tmem119, have contributed
in various degrees toward microglial identification (12, 14–
20). However, loss of these markers at the transcript level are
observed when microglia are perturbed and some of these
markers are lost at the protein level, highlighting the need
for careful validation of these markers as microglial-specific
given their expression is dependent upon the disease context
(8, 11–13). The Cx3cr1CreER:R26-tdTomatomouse strain permits
binary discrimination of the microglia from other immune cells.
The model utilises the high expression of Cx3cr1 in microglia
and the longevity (as low level self-replication) of microglia in
comparison to other immune cells (14).
In this study, we validate theCx3cr1CreER:R26-tdTomato strain
as sensitive and specific for tagging retinal microglia and perform
mRNA-Sequencing on microglia obtained from individual
retina during and after resolution of acute inflammation
induced by intravitreal injection of LPS [the endotoxin-induced
uveitis (EIU) model]. We show that the retinal microglia
undergo acute transcriptional changes which resolve to their
original homeostatic state by 2 weeks and support microglial
heterogeneity in response to inflammatory signals.
MATERIALS AND METHODS
Mice
Cx3cr1CreER:R26-tdTomato mice on a C57BL/6J background
were provided by Clemens Lange (University of Freiburg,
Germany). Breeding colonies of homozygotes were established,
and offspring crossed with C57BL/6J mice to generate
heterozygotes for experiments. Genotyping (via PCR) of
breeding pairs was performed. Mice were confirmed as negative
for the Rd8mutation (21).
All mice were housed at the University of Bristol Animal
Services Unit under specific pathogen free conditions with
food and water ad libitum. All procedures were conducted in
concordance with theUnited KingdomHomeOffice licence (PPL
30/3281) and were approved by the University of Bristol Ethical
Review Group. The study also complied with the Association for
Research in Vision and Ophthalmology (ARVO) Statement for
the Use of Animals in Ophthalmic and Visual Research.
Tamoxifen Preparation and Administration
Tamoxifen (T5648; Sigma-Aldrich, Poole, UK) was dissolved in
corn oil (C8267; Sigma-Aldrich) to a concentration of 20 or 5
mg/mL, for subcutaneous injection and topical administration,
respectively. The solutions were freshly prepared by overnight
incubation in an orbital shaker at 42◦C and 300 rpm. Mice were
injected with 200 µL subcutaneously [100 µL into both the lower
(inguinal) left and right quadrants using a 25G needle] on days
1 and 3; alternatively, mice were administered 10 µL topically to
the eye three times daily (minimum gap of 2 h between dosing)
for up to 4 days.
Induction of EIU
Prior to anesthesia, pupils were dilated using topical tropicamide
1% w/v and phenylephrine 2.5% w/v (Minims; Chauvin
Pharmaceuticals, Romford, UK). Mice were anaesthetised by
intraperitoneal injection of 90 µL/10 g body weight of a solution
containing 6 mg/mL ketamine (Ketavet; Zoetis Ireland Ltd.,
Dublin, Ireland) and 2 mg/mL Xylazine (Rompun; Bayer plc,
Newbury, UK) mixed with sterile water.
Mice were selected for injection (or to be used as a control)
in a constrained randomised order within blocks using Excel
2016 (Microsoft, Redmond,WA); blocks were dependent on cage
allocations, which itself was dependent on the litter they were
derived from. The allocations ensured that all experiments had
littermate controls.
Intravitreal injections were performed as previously described
(22). In brief, 2 µL volume of PBS containing 10 ng LPS from
E. coli 055:B5 (Sigma-Aldrich) was delivered into the intravitreal
space via the pars plana, using an operating microscope and a 33-
gauge needle on a microsyringe (Hamilton Company, Reno, NV)
under direct visualisation. Immediately following injection, 1%
w/w chloramphenicol ointment (Martindale Pharma, Romford,
UK) was applied topically, with the animals monitored and kept
on a heat-pad during recovery.
EIU Clinical Assessment
At selected time-points (4 h, 18 h, and 2 weeks) post-injection,
pupils were dilated and mice anaesthetised for clinical
assessment. The Micron IV retinal imaging microscope
(Phoenix Research Laboratories, Pleasanton, CA) was used
to capture optical coherence tomography (OCT) scans, and
brightfield and fluorescence fundal images.
Prior to imaging, the Micron IV CCD and OCT were
calibrated in accordance with the manufacturer’s protocol. The
gain was set to +3 dB and the FPS to 15, or +12 dB and 2
for brightfield and tdTomato fluorescence imaging, respectively.
For tdTomato imaging, a 550/25 nm bandpass excitation and
590 nm longpass emission filter were used (Edmund Optics,
Barrington, NJ).
For OCT, the parameters were defined according to the
manufacturers protocol, and scans were taken 30 times in
rapid succession and averaged. Full-length B-scans were taken
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horizontally and vertically with the optic disc centered. Images
were stored in the TIFF file format.
Isolation and Flow Cytometric Phenotyping
of Retinal Immune Cells
Eyes were dissected in 100 µL ice-cold PBS with aqueous,
vitreous, and retina extracted by a limbal incision, lens removal
and transfer into a 1.5mL microcentrifuge tube. The tissue was
mechanically disrupted by rapping the tube along an Eppendorf
rack 12 times before transfer into a 96-well 60 µm nylon mesh
filter plate (Merck Millipore, UK). The plate was centrifuged at
400 xg for 5min and the supernatant aspirated. The remaining
cell pellet was resuspended in FACS buffer (PBS supplemented
with 3% v/v Foetal calf serum and 0.9 mg/mL sodium azide) and
transferred to a 96-well V-bottom plate for FACS staining.
Single cell suspensions from spleen and brain were generated
by mechanical dissociation through a 70 µm cell strainer
with a syringe plunger. Cells were centrifuged at 400 xg for
3min, erythrocytes lysed using ammonium-chloride-potassium
(ACK) buffer, and cells resuspended in FACS buffer. Cells
were incubated with purified rat anti-mouse CD16/32 Fc
block [Clone 2.4G2; Becton Dickson (BD) Biosciences, Oxford,
UK] and 7-aminoactinomycin D (7AAD; Thermo Fisher
Scientific, Waltham, MA) diluted in FACS buffer for 20min
at 4◦C. Cells were then incubated with an antibody cocktail
containing fluorochrome-conjugatedmonoclonal antibodies (see
Supplementary Table 1) against various mouse cell-surface
markers for 20min at 4◦C. All mAbs were titrated and tested
using control tissues.
Cell suspensions were acquired using a 4-laser Fortessa X-
20 flow cytometer (BD Cytometry Systems, Oxford, UK).
Compensation was performed using OneComp eBeads
(Thermo Fisher Scientific), Anti-Rat Ig, κ/Negative Control
Compensation Particles Set (BD Biosciences), or AbC total
antibody compensation bead kit (Thermo Fisher Scientific).
To compensate tdTomato, cell suspensions prepared from
Cx3cr1CreERR26-tdTomato homozygote brains were used.
Fluorescence-minus-one (FMO) controls were used to assist
in gating of the markers selected for validation. Following
acquisition, analysis was performed using FlowJo software
(Treestar, San Carlos, CA).
Fluorescence-Activated Cell Sorting
Retinal single cell suspensions were re-suspended in 200
µL FACS buffer containing DRAQ7 (DR77524; Biostatus,
Shepshed, UK). Livemicroglial cells (tdTomatohi DRAQ7−) were
immediately sorted using a BD Influx Cell Sorter. Retinal samples
were prepared in small batches in order to maintain cell viability
and ensure high quality RNA.
Cells were sorted into 0.2 mL endonuclease-free tubes
containing 0.05 µL RNase inhibitor, 0.95 µL lysis buffer, and a
variable amount of nuclease-free water depending on the number
of cells collected: 9.5 − ( x850∗3) µL, where x is the number of
cells isolated, using components of the SMART-Seq v4 Ultra
Low Input RNA Kit for Sequencing (Takara Bio USA, Inc.,
Mountain View, CA). Samples were sorted in a constrained
randomised order in blocks; blocks were made as small as
possible and consisted of a balance of every experimental group
to ensure that time- or order-dependent (batch) effects of sorting
were mitigated.
mRNA-Sequencing
Sample and Library Preparation
Samples were prepared using the SMART-Seq v4 Ultra Low Input
RNAKit for Sequencing, according to the usermanual, to convert
the mRNA into cDNA and amplify by Long Distance (LD) PCR
(16 cycles for 600 cells). cDNA was isolated using the Agencourt
AMPure XP Kit (Beckman Coulter, Brea, CA) and quantified
using the Agilent High Sensitivity DNA Kit on an Agilent 2100
Bioanalyser (Agilent Technologies, Santa Clara, CA). The library
preparation was performed using the Nextera XT DNA Library
Preparation Kit (Illumina Inc., San Diego, CA).
Sequencing and Analysis
Samples were sequenced to depths of up to 16.7 million
single-end 75 nt length reads per sample using the Illumina
NextSeq 500/550 High Output v2 kit (75 cycles) on an Illumina
NextSeq 500 Sequencing System. Image analysis, base calling, and
generation of sequence reads were produced using the NextSeq
Control Software v2.0 (NCS) and Real-Time Analysis Software
v2 (RTA). Data was converted to FASTQ files using the bcl2fastq2
v2.20 software (Illumina Inc.).
Sequencing data was initially quality-checked using FastQC1,
before alignment and initial analysis. The data was processed
through an analysis pipeline using the Partek Flow (Build
version 6.0.17.0614; Partek Inc., St. Louis, MO) software with
the following task nodes (non-default parameters are specified
in brackets): Trim adapters (inputting Nextera XT Index Kit
v2 adapter sequences2, Trim bases (From 3
′
end, 1 base),
Trim bases [from 3
′
end with minimum quality score (Phred)
of 30], Align reads using STAR (2.5.3a using mm10 as the
reference index), Quantify to transcriptome (Partek E/M using
mm10 – Ensembl Transcripts release 89 as the reference index)
(Supplementary Figures 1, 2).
The Partek Flow data output was further analysed using
Partek Genomics Suite (PGS) (Version 6.6, Build 6.16.0812). PGS
normalises data using the reads per kilobase million (RPKM)
approach and performs differential gene expression analysis
using an ANOVA model; a gene is considered differentially-
expressed (DEG) if it has an FDR step-up p ≤ 0.05 and a fold-
change≥±2. The data was subsequently analysed for enrichment
of GO terms and the KEGG pathways; a pathway is considered
significantly-enriched if the enrichment score is ≥3 (equivalent
to a p ≤ 0.05). The fold-change and p-values of all genes were
then imported into Ingenuity Pathway Analysis (IPA) version
01-13 (Qiagen Bioinformatics, Aarhus, Denmark) and analysed
according to the manual. Pathways were considered significantly
1SimonAndrews, BrianHoward, Phil Ewels. FastQC: a quality control tool for high
throughput sequence data 2015. Available online at: http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/.
2Illumina. Illumina Adapter Sequences 2017. Available online at: https://support.
illumina.com/content/dam/illumina-support/documents/documentation/
chemistry_documentation/experiment-design/illumina-adapter-sequences-
1000000002694-11.pdf).
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altered if they had a p ≤ 0.05 and a z-score (directionality score)
≥±2. PGS and IPA were both used to generate figures.
Quantitative PCR
The remaining cDNA generated from the sorted cells was used
for transcript-level validation. qPCR was performed using the
TaqMan Universal Master Mix II, with UNG (4440038) and
TaqMan gene expression probes (4331182) on a Quantstudio
3 Real-Time PCR system (A28137; all products from Thermo
Fisher Scientific). Samples were run in technical duplicate, using
1 ng as the input amount, and analysed using the equation:
2Cq(mean (control))−Cq(sample).
The probes used were: Bst2 (mm1609165_g1),
C5ar1 (mm00500292_s1), Cd44 (mm01277161_m1),
Fas (mm01204974_m1), Lair1 (mm00618113_m1),
Mertk (mm00434920_m1), Milr1 (mm01242703_m1),
P2ry12 (mm01950543_s1), Siglech (mm00618627_m1),
Slamf1 (mm00443317_m1).
Immunohistochemistry
Eyes from euthanised mice were enucleated and fixed in 4% v/v
PFA for 1 h before dissection. The anterior portion of the eye
(cornea, iris, ciliary body, and lens) was carefully removed and an
eyecup prepared. The eyecup tissue was blocked in 5% v/v normal
goat serum (Vector Laboratories, CA, USA), 1% v/v BSA, and 3%
v/v Triton x-100 (both Sigma Aldrich) in PBS for 4 h at room
temperature with gentle shaking. Eyecups were then incubated
at 4◦C overnight with a rabbit anti-mouse anti-RFP mAb (600-
401-379; Rockland Immunochemicals Inc., Limerick, PA) and
for target validation experiments a Super Bright 600-conjugated
anti-mouse CD44 mAb (Supplementary Table 1) was used in
combination. After thorough washing with PBS, samples were
incubated overnight with the secondary antibody goat anti-rabbit
Alexa-633 (A21070; Thermo Fisher Scientific). The eyecups
were washed again, and the retina carefully removed and
flatmounted in Vectashield hard-set antifade mounting media
(H-1400; Vector Laboratories Ltd., Peterborough, UK) and
imaged on a Leica SP5-AOBS confocal laser scanningmicroscope
(Leica Microsystems Ltd., Wetzlar, Germany). Images were
acquired with an xy pixel size ≤200 nm, and a z-step size of
≤400 nm.
Statistical Analysis and Image Processing
Data were analysed using GraphPad Prism 7 software (GraphPad
Software Inc., San Diego, CA). The One-way ANOVA with
Tukey’s multiple comparisons test was used to compare
multiple groups of data to a control group. A p ≤ 0.05 was
considered significant.
Huygens professional software (Scientific Volume Imaging
B.V., Hilversum, The Netherlands) was used to deconvolve
the Micron IV fluorescent images and fluorescence microscopy
(Supplementary Figure 3). For the Micron images, the following
parameters were used: lens immersion = 1.343 [refractive index
of the 0.2% w/w carbomer eye gel (23)], embedding = 1.377
(24), peak emission = 581 nm, numerical aperture = 1.25, and
xy pixel size of 130 nm; the background was estimated at 2 and a
signal-to-noise ratio of 15 was used. Hot pixel correction (with a
sensitivity of 4) was used prior to deconvolution. For fluorescence
microscopy, the parameters were imported from the microscope
and the default settings were used.
Microscopy images were processed using the Leica LAS X
software (Leica Microsystems Ltd.) and FIJI [a distribution of
ImageJ (25)]. Other images, and figures, were processed using
Photoshop (Adobe Inc., San Jose, CA).
RESULTS
Subcutaneous and Topical Tamoxifen
Administration Regimes Tag Retinal
Microglia in the Cx3cr1CreER:R26-tdTomato
Mouse Line
Activation of the CreER system requires administration of
tamoxifen or 4-hydroxytamoxifen, and various methods of
administration are frequently employed such as subcutaneous
injection and oral gavage (14, 26). Moreover, an efficacious
4-day topical regime for activating CreER systems within
the eye was recently described (27). Therefore, we initially
tested which tamoxifen administration regime tagged retinal
microglia efficiently while minimising systemic immune cell
labelling to preclude analysing cells subsequently recruited
during inflammation.
Five regimes were tested, spanning from 1- to 4-day topical
and subcutaneous administration. A no-tamoxifen control
was included. At 4 weeks post-tamoxifen treatment, flow
cytometric analysis of the retinas quantified the proportion
of CD45int CD11b+ microglia (in a naïve retina) that
were tdTomatohi as corroborated with fluorescent fundal
imaging (Figures 1A,B). Microglia displayed a “resting” ramified
morphology (Figure 1C). The 3- and 4-day topical, and the
subcutaneous regime tagged ≥95% of microglia whereas the no-
tamoxifen controls had 45% tagged constitutively (Figure 1D).
All tdTomatohi cells were microglia, indicating specificity in the
normal adult mouse retina.
Cx3cr1CreER:R26-tdTomato Mice Exhibit
Typical Kinetics of the EIU Model
The stability of microglial tagging during inflammation is
pivotal to the isolation of pure populations of microglia
for downstream transcriptomic assessment before, during,
and after inflammation. To determine this, we utilised
endotoxin-induced uveitis (EIU), a self-resolving model of
acute Toll-like receptor 4 (TLR4)-mediated ocular inflammation,
that following a single inflammatory insult generates acute
immune cell tissue infiltration (28, 29). We confirmed disease
kinetics in the Cx3cr1CreER:R26-tdTomato heterozygotes
replicated our previous data in C57BL/6J mice (22). A
time-course using OCT, deconvolved fluorescent fundal
imaging, and confocal microscopy confirmed tdTomato
expression throughout the expected time course of disease
(Figure 2). Intravitreal administration of LPS results in peak
cellular infiltrate at 18 h, which then resolves by 2 weeks
(Figure 2A). Fluorescent fundal imaging demonstrates that
the uniform distribution of microglia is altered in response
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FIGURE 1 | Sensitivity of microglial recombination induced in Cx3cr1CreER:R26-tdTomato mice using different tamoxifen administration regimes. (A) A representative
flow cytometric gating strategy used to identify microglia in a naïve retina based on CD45 and CD11b expression. (B) Representative deconvolved tdTomato
fluorescent fundal images of mice with representative tdTomato histograms (unit area scaling) on gated microglia from various tamoxifen administration regimes. (C)
Confocal microscopy from a 3-day topical regime naïve retina shows microglia with a physiological ramified morphology, suggesting no gross perturbations in the
microglia as a consequence of the transgenic model. (D) Aggregate data demonstrating the percentage of microglia that were tdTomatohi (as quantified by flow
cytometry) shows that a 3- and 4-day topical, in addition to subcutaneous, regimes result in full microglial tagging (n = 3–6). None, no tamoxifen administered; 1D,
1-day topical tamoxifen regime; 2D, 2-days topical tamoxifen regime; 3D, 3-days topical tamoxifen regime; 4D, 4-days topical tamoxifen regime; Sc, subcutaneous
tamoxifen regime. ****p ≤ 0.0001, ns, not significant. Scale bar = 30µm.
to LPS, with defined areas of tdTomato+ cell accumulation
observed at peak disease (Figure 2B). Confocal microscopy
confirmed tdTomato+ cells in the naïve retina with a
ramified morphology that became amoeboid at peak and
recovered to a ramified appearance by 2 weeks post-EIU
induction (Figure 2C).
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FIGURE 2 | The kinetics of endotoxin-induced uveitis (EIU) in the Cx3cr1CreER:R26-tdTomato mouse strain. (A) OCT images showing disease-course in a single
mouse (3-day topical regime), demonstrates the presence of infiltrating cells at 18 h post-injection with resolution by 2 weeks. (B) Deconvolved fluorescent fundal
images acquired simultaneously show few changes in the distribution of tdTomato+ cells at 4 h post-injection, but changes at 18 h which resolve by 2 weeks. (C)
Confocal microscopy of the tdTomato+ cells demonstrate a ramified toward amoeboid shift at 4- and 18 h post-injection that reverts to a ramified morphology by 2
weeks. Representative images of single cells are shown in the lower panel to highlight morphological changes. EIU, endotoxin-induced uveitis; OCT, optical coherence
tomography. Scale bars = 30µm.
Three-Day Topical Tamoxifen Induction
Ensures Specificity of tdTomato Labelling
in Microglia
With tdTomato expression confirmed as stable in the microglial
population, we sought to determine whether this was exclusive
to microglia in the context of immune cell infiltration, validating
accurate isolation of themicroglial transcriptome. To confirm the
specificity for retinal microglial tagging during inflammation, we
examined tamoxifen regimes which efficiently tagged microglia
(3- and 4-day topical, and subcutaneous) in addition to a no-
tamoxifen control. Flow cytometry was performed on peripheral
tissues and a small portion of myeloid cells were observed as
tdTomatohi, primarily when tamoxifen was administered via the
subcutaneous route (Supplementary Figure 4). However, to test
the specificity within the retina, inflammation was required.
Retinas were retrieved at the peak cellular infiltrate
stage of EIU (18 h) and flow cytometry was performed
(Supplementary Figure 5). Single, live cells identified as
tdTomatohi were assessed by conventional microglia markers
of CD45int and CD11b+ (Figures 3A,B). A small proportion
(5%) of all single live retinal cells express very low levels of
tdTomato (Figure 3A, boxed), as described in the tdTomato
reporter mice (in the absence of Cre/CreER)3 due to a failure of
a small proportion of ribosomes to terminate translation when
reaching the stop codon that precedes tdTomato (30). Using this
gating strategy, analysis from the 4-day topical and subcutaneous
regimes demonstrates the presence of an additional population
of non-microglial (CD45hi CD11b−) cells that were identified
3The Jackson Laboratory. 007914 - B6.Cg-Gt(ROSA)26Sor 2019. Available online
at: https://www.jax.org/strain/007914.
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FIGURE 3 | The specificity of microglial tagging for different tamoxifen administration regimes in the Cx3cr1CreER:R26-tdTomato mouse strain during active
inflammation. (A) Peak EIU retinas following different tamoxifen administration regimes were prepared for flow cytometry. Live, cell singlets were gated based on
tdTomatohi expression. A small proportion (5%) of all live cells expressed low levels of tdTomato (boxed). (B) TdTomatohi cells were gated based on CD45int and
CD11b+ expression, and in the 4-day and subcutaneous tamoxifen treated groups, non-microglial cells (CD45hi CD11b−) were present (circled). (C) Gating microglia
based on CD45 and CD11b expression alone results in the inclusion of infiltrating immune cells (tdTomato−, blue) in addition to retinal microglia (tdTomatohi, orange)
but exclusion of cells not fitting the microglial expression profile (CD45hi/lo, red). (D) Aggregate data on the percentage specificity for microglia demonstrates that the
3-day topical route results in high specificity for microglia using tdTomato. The CD45int/CD11b+ group uses the microglial gating strategy (from live cell singlets
without using tdTomato) shown in panel B for a comparison of the mouse strain to conventional microglial identification strategies (n = 2–5). (E) Total counts from
naïve and peak EIU retinas, following the 3-day topical tamoxifen regime, demonstrate equivalent numbers of tdTomatohi cells (n = 6–8). None, no tamoxifen
administered; 3D, 3-days topical tamoxifen regime; 4D, 4-days topical tamoxifen regime; Sc, subcutaneous tamoxifen regime. **p ≤0.01, ns, not significant.
in the tdTomatohi subset (Figure 3B). Gating with CD45int
and CD11b+ but not tdTomato leads to the inclusion of
non-microglial cells (Figure 3C) and greatly compromises
specificity. The 3-day topical and no-tamoxifen control retained
the specificity of tdTomato for microglia (Figures 3B,D), but
as shown previously a no-tamoxifen control does not fully
label the microglial population (Figure 1). As our approach for
distinguishing microglia (CD45int CD11b+ tdTomatohi) from
the tdTomatohi group could include non-microglia that possess
a similar transcriptional profile to retinal microglia, the total
counts of the CD45int CD11b+ tdTomatohi group, from naïve
and peak EIU retinas (3-day topical tamoxifen), were compared
and no significant difference was observed confirming a pure
microglial population (Figure 3E). All subsequent experiments
performed used the 3-day topical tamoxifen regime.
Microglia Undergo Acute Transcriptional
Changes During EIU That Fully Normalise
to a Baseline State by 2 Weeks
The 3-day tamoxifen regime in the Cx3cr1CreER:R26-tdTomato
strain provides the sensitivity and specificity required for
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FIGURE 4 | mRNA-Sequencing of microglia during and after EIU reveals transcriptional alterations that fully resolve. (A) Hierarchical clustering of
differentially-expressed genes (DEGs) shows differences in the kinetics of the microglial transcriptome during EIU. Boxes highlight clusters of genes with different
(Continued)
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FIGURE 4 | kinetics, and a restoration back to a homeostatic signal by 2 weeks (n = 5–10). (B) Scatterplots show changes in expression of previously described
microglial genes to include a homeostatic gene (Gpr34), homeostatic transcription factor (Mafb), generic activation gene (Cxcl10), acute LPS-response gene
(Map3k8), and “primed microglia” gene (Axl). (C) Heatmaps highlight canonical pathways, which were significantly different during at least one timepoint, change in
direction (z-score) and p-value over time (n = 5–10); the pathways are in ascending order based on their overall (summary) p-value. The raw canonical pathway figures
are presented in Supplementary Figure 6. EIU, endotoxin-induced uveitis. *p ≤ 0.05, **p ≤ 1*10−3, ***p ≤ 1*10−6, ****p ≤ 1*10−9.
reliable identification and isolation of distinct retinal microglia
populations from other populations of infiltrating immune cells.
To characterise changes in the microglial transcriptome during
and after resolution of EIU, FACS (based on tdTomato) of 600 live
microglia was performed from individual retinas collected at 4 h,
18 h, and 2 weeks post-injection in addition to naïve mice. The
majority of these samples (28/30) yielded high-quality cDNA for
sequencing using a validated pipeline (Supplementary Figure 1).
Our approach identified 1,069 unique differentially expressed
genes (DEGs; 613 at 4 h, 537 at 18 h, and 0 at 2 weeks)
visualised by hierarchical clustering, revealing a highly plastic
transcriptome with most up-regulated genes being mutually
exclusive at different timepoints. Boxes highlight clusters of
genes that were normal at 4 h but up-regulated at 18 h (yellow),
those which were up-regulated at 4 h but not 18 h (brown),
those which were up-regulated at both time-points (green), those
which were down-regulated at 4 h but recovered to pre-EIU
levels by 18 h (light blue), and those which were down-regulated
at both 4- and 18 h (black). Restoration back to a homeostatic
signal was observed by 2 weeks because unsupervised clustering
failed to distinguish naïve and 2-week post-injection samples
(Figure 4A). A multitude of expected gene changes based on
published literature were observed, including downregulation
of microglial homeostatic genes (Gpr34, Mafb), expression of
microglial activation and LPS-response genes (Cxcl10, Map3k8),
in addition to no change in the “primed microglia” gene Axl
(11, 12, 17, 31) (Figure 4B). A heatmap demonstrates the
change in z-score over time of canonical pathways identified
as significantly different (Figure 4C). The original canonical
pathways (including bars showing exact p-values) are presented
in Supplementary Figure 6.
Enriched GO terms (enrichment score) when naïve and 4 h
EIU groups were compared included: immune system process
(60.9), regulation of cytokine production (56.0), and response to
stress (52.7). Similarly, the enriched KEGG pathways included:
NF-Kappa B signaling pathway (34.1), toll-like receptor signaling
pathway (31.7), and TNF signaling pathway (25.3). For the
naïve and 18 h EIU comparison GO terms included: cytosolic
part (89.7), extracellular organelle (70.67), translation (65.8),
and immune system process (29.8); enriched KEGG pathways
included: ribosome (58.8) and proteasome (42.9). LPS was found
to be a “master regulator” by IPA, indicating agreement of our
data with the curated lists and pathways.
Flow Cytometry and Fluorescence
Microscopy Validate Key Transcriptional
Alterations
Our next aim was for orthogonal validation of key and
novel transcriptional changes, both at the RNA and protein
level. Markers for validation were selected by systematic
assessment based on magnitude of the relative change in
expression, novelty, lack of prior validation at the protein
level, whether they were a previously suggested microglial
marker, were in contrast to or appeared crucial in light of
other reports, and lastly the availability of testing reagents
(Supplementary Figure 7). Ultimately, the final set of 10
markers selected represent a variety of expression patterns
and kinetics to match the plastic landscape identified by
hierarchical clustering. In line with published reports and
an activated state, pro-inflammatory markers (Slamf1,
C5ar1, Fas, and Cd44) were all upregulated at 4 h following
LPS challenge. In addition, a novel microglial associated
transcript, Milr1 (a negative regulator of mast cell activation)
and Bst2 (a previously validated marker of late activation)
were elevated by 18 h. In contrast, constitutively expressed
microglial genes, including homeostatic genes (e.g., P2ry12,
Siglech, Mertk, and Lair1) were down-regulated at the
early time-point. In general, qPCR analysis validated
the transcript-level changes observed at each time-point,
confirming resolution and return to baseline levels by 2
weeks (Figure 5).
Flow cytometric analysis demonstrates increased expression
in SLAMF1, MILR1, C5AR1, CD44, BST2, and LAIR1 at
18 h post-injection (Figures 6A–D). Furthermore, differences
in the proportion of marker-positive cells were evident, with
C5AR1, CD44, and BST2 upregulated in the majority of
microglia (>50%), in contrast to the other makers which
were elevated in a smaller fraction (<20%) of cells. The
upregulation of CD44 was also confirmed in retinal flatmounts
at 18 h using fluorescence microscopy (Figure 6E). Whilst
P2RY12 was highly expressed in naïve microglia (>80%),
no change in expression in response to LPS were observed.
Similarly, low level SIGLECH, MERTK, and FAS expression
in naïve populations remained unchanged and restricted to a
small percentage of the microglia (<10%). We also compared
expression of P2RY12 and SIGLECH on CD45+ cells, as both
are previously suggested markers that differentiate microglial
populations from other immune cells (17, 20). Flow cytometric
analysis clearly demonstrates that both markers are equally
expressed on CD45+ infiltrating cells, indicating these markers
exhibit poor specificity for retinal microglia during the acute
response (Figure 6F).
Stratifying Microglia Using C5AR1
Identifies Both Generalised and Restricted
Microglial Responses
Recent reports show that C5ar1 was one of several markers
that was enriched in a subset of brain microglia (identified
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FIGURE 5 | Transcript changes in selected markers, using cDNA generated from 600 sorted microglia, over a time-course of EIU. (A,C) RPKM values are shown for
the 10 selected markers (B,D) in-line vertically with matching qPCR validation. EIU, endotoxin-induced uveitis; FC, Fold-change; RPKM, reads per kilobase of
transcript per million mapped reads. *p ≤ 0.05, ****p ≤ 0.0001, ns, not significant.
by sc-mRNA-Seq data) responding to systemic LPS challenge
in vivo (13). Furthermore, mounting evidence from numerous
reports identify heterogeneity in the microglial response during
other pathological states (8, 32). We therefore examined
whether stratifying microglia based on C5AR1 expression would
delineate differences in the markers selected for validation,
highlighting specificity to this subset of C5AR1-expressing
cells, or generalised expression across the whole population
of microglia.
Microglia were stratified into three main groups: C5AR1neg,
C5AR1lo, and C5AR1hi. The C5AR1-expressing microglia were
sub-stratified based on whether the C5AR1 expression was
equivalent tomicroglia observed within a naïvemouse (C5AR1lo)
or whether expression was elevated (C5AR1hi; Figure 7A).
C5AR1hi expression correlated to the extent of immune
cell (CD45+ TdTomato−) infiltrate within the retinas and
represents a potential microglial marker for disease scoring
(Figure 7B). Flow cytometric analysis compared expression
of the other surface markers in C5AR1neg and C5AR1hi
subsets, as two distinctive populations, in naïve and peak
EIU retinas. Delineating the two populations on this basis
demonstrates elevation of several markers (SLAMF1, FAS,
MILR1, and LAIR1) which are restricted to the C5AR1-
expressing microglia (Figure 7C). In contrast CD44 and BST2
were enriched within the C5AR1-expressing population but also
expressed by a large proportion of the C5AR1neg microglia,
thus representing more generalised markers of microglial
perturbation (Figure 7D).
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FIGURE 6 | Changes in protein expression of selected markers in microglia over a time-course of EIU. (A,C) A representative flow cytometric histogram is shown for
the 10 selected markers (B,D) in-line vertically with matching scatterplots of the aggregate flow cytometry data summarising the percentage of microglia positive for
each marker at each timepoint. Gates were drawn with the assistance of fluorescence-minus-one (FMO) controls (light blue). (E) Confocal microscopy also confirms
the upregulation of CD44 in microglia during EIU. (F) Flow cytometric analysis demonstrates P2RY12 and SIGLECH expression on CD45+ tdTomato− non-microglial
immune cells (blue) and CD45+ tdTomato+ microglia (red) at 18 h EIU. % +ve, percentage positive; EIU, endotoxin-induced uveitis. **p ≤ 0.01, ****p ≤ 0.0001, ns, not
significant. Scale bars = 30 µm.
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FIGURE 7 | Stratifying microglia using C5AR1 expression identifies both restricted and generalised responses. (A) A histogram shows microglial C5AR1 expression in
a fluorescence-minus-one (FMO) control (blue), naïve retina (purple), and at 18 h EIU (orange). (B) Immune cell infiltrate correlates with C5AR1hi expression in microglial
populations (p = 0.0298). (C) Stratifying microglia into C5AR1− and C5AR1hi (elevated above the naïve level of expression) identifies changes in cell-surface protein
expression that are restricted to C5AR1-expressing microglia, (D) but also changes in proteins which are generalised microglial responses (not exclusive to, but
somewhat enriched in, the C5AR1-expressing microglia). ****p ≤ 0.0001, ns, not significant.
DISCUSSION
Single eye mRNA-Seq revealed inflammation-responsive
transcriptional changes in retinal microglia following LPS
stimulation which resolve within 2 weeks, confirming the
potential for these cells to reset their homeostatic state. In line
with the literature, our data confirms recognised patterns of
altered gene expression in homeostatic and activation pathways,
an absence of changes in “primed microglia” genes, and identifies
enriched pathways relating to immune function.
Hierarchical clustering of the 1,069 DEGs identified reveals
a high level of plasticity in the microglial transcriptome, with
the majority of up-regulated genes at early (4 h) and peak (18 h)
being mutually exclusive across the time-points. At the transcript
level at least, this highlights a consensus group of microglial
LPS-response genes including (Slamf1, C5ar1, Fas, Cd44, Milr1,
and Bst2). In contrast, we highlight a common cluster of
down-regulated genes, including homeostatic regulators (P2ry12,
Siglech,Mertk, Lair1).
Orthogonal validation by qPCR of the 10 markers selected
representing key and novel transcripts, confirmed the RNA-
Seq findings. However, altered expression of some of these
membrane-associated makers did not translate to changes at
the protein level, as determined by flow cytometry. In part,
this may reflect the presence of intracellular protein that our
flow cytometric approach did not detect, or represents genuine
discrepancies between the transcriptome and proteome, as
these are not always in direct proportion (33–35). Our results
emphasise caution in reading out RNA-Seq alone as a true
representation of the cell’s activity and highlight the need for
orthogonal validation. Nonetheless, the single eye mRNA-Seq
approach identified key and novel transcriptional changes which
informed subsequent testing on a smaller number of markers via
low-throughput approaches.
We confirmed and validated some of the transcriptional
changes by flow cytometry but found that the differences were
enhanced, and an additional marker (FAS) was identified as
significantly different, when microglia were first stratified based
on their C5AR1 expression as suggested via a transcripts-
led report (13). Furthermore, we identified markers which
were exclusive to the C5AR1-expressing microglia (SLAMF1,
FAS, MILR1, and LAIR1), but also generalised markers which
were not (CD44 and BST2). This agrees with other reports
which suggest that C5AR1 is needed for microglial polarisation
to pro-inflammatory states, and that its knock-out improved
outcomes in an Alzheimer’s model (36). Furthermore, microglial
heterogeneity has already been reported in Alzheimer’s disease,
light-damage models, and in response to LPS stimulation in
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vivo (8, 13, 32). Understanding microglial heterogeneity, and
identifying changes which are exclusive to subpopulations, is
critical for developing targeted therapies.
Conflicting with previous reports investigating LPS-responses
and experimental autoimmune encephalomyelitis (EAE), we did
not find significant down-regulation of P2RY12 upon microglial
activation (11, 13). In EAE, the microglia exhibit a chronic
inflammatory state different to the acute LPS response, whilst
the report investigating the LPS response used a systemic dose
400 times greater than our own local dose and had an endpoint
24 h post-injection which could explain the discrepancy. We
suggest microglial loss of P2RY12 as context-dependent, for
example when subject to a significant immune stimulus or
persistent inflammation.
For this investigation, a clear marker to distinguish long-
lived, yolk-sac derived microglia from infiltrating myeloid cells
was critical, particularly during peak ocular inflammation at
18 h post-LPS injection. The Cx3cr1CreER:R26-tdTomato line
has been validated for this approach previously (14, 37), but
as we demonstrate the systemic tamoxifen administration
also labels peripheral leukocyte populations which are
recruited to the eye during inflammation. Modifying a
recently published protocol (27) demonstrates that the 3-
day topical tamoxifen administration regime is robust in
labelling retinal microglia in both a sensitive (Figure 1)
and specific (Figure 3) manner, superior to the established
subcutaneous route. Shortening of the originally-published
topical protocol from 4 days to three is likely possible due to
the very high expression of Cx3cr1 in microglia and reduces
confounders of animal handling and stress to the mice as
a refinement4 The high expression of Cx3cr1 by microglia
also explains why mice underwent tamoxifen-independent
(or constitutive) recombination in 45% of the microglia
as tamoxifen-independent recombination (constitutive
receptor activation of the CreER) is a well-characterised
phenomenon (38–40).
With other administration routes, we found that the specificity
for microglia was reduced during ingress of immune cells with
inflammation. This supports recent studies of microglia that
highlight the need to confirm the specificity for microglia in their
disease model and employ techniques with single-cell resolution
to resolve the non-microglial cell populations (8, 41).
Taking all our data together, we show that three previously
suggested markers (P2RY12, CD44, and SIGLECH) exhibit poor
specificity for microglia. However, with the Cx3cr1CreER:R26-
tdTomato line it remains possible to validate potential markers,
assuming the line retains specificity for microglia across disease
contexts. Microglial subtypes can exhibit both differential and
generalised responses to LPS.
In summary, we demonstrate that the homeostatic threshold
of retinal microglia is reset following an acute inflammatory
4National Centre for the Replacement R, Reduction of Animals in R. The 3Rs |
NC3Rs 2018. Available online at: https://www.nc3rs.org.uk/the-3rs.
insult and identify potential markers for delineating the
heterogeneity of microglia that may be used depending on
context of retinal perturbation.
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